GENOWAY SA (ALGEN.PA) Stock Fundamental Analysis
Europe - Euronext Paris - EPA:ALGEN - FR0004053510 - Common Stock
2.55 EUR
-0.05 (-1.92%)
Overall ALGEN gets a fundamental rating of 5 out of 10. We evaluated ALGEN against 82 industry peers in the Biotechnology industry. ALGEN has only an average score on both its financial health and profitability. ALGEN is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
ALGEN had positive earnings in the past year.
In the past year ALGEN had a positive cash flow from operations.
In multiple years ALGEN reported negative net income over the last 5 years.
The reported operating cash flow has been mixed in the past 5 years: ALGEN reported negative operating cash flow in multiple years.
1.2 Ratios
With a decent Return On Assets value of 3.96%, ALGEN is doing good in the industry, outperforming 78.31% of the companies in the same industry.
The Return On Equity of ALGEN (7.06%) is better than 77.11% of its industry peers.
ALGEN's Return On Invested Capital of 6.13% is amongst the best of the industry. ALGEN outperforms 81.93% of its industry peers.
ALGEN had an Average Return On Invested Capital over the past 3 years of 5.56%. This is significantly below the industry average of 13.22%.
The last Return On Invested Capital (6.13%) for ALGEN is above the 3 year average (5.56%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.96% | ||
| ROE | 7.06% | ||
| ROIC | 6.13% |
ROA(3y)4.35%
ROA(5y)1.91%
ROE(3y)7.98%
ROE(5y)2.79%
ROIC(3y)5.56%
ROIC(5y)N/A
1.3 Margins
Looking at the Profit Margin, with a value of 5.86%, ALGEN belongs to the top of the industry, outperforming 80.72% of the companies in the same industry.
With a decent Operating Margin value of 8.09%, ALGEN is doing good in the industry, outperforming 75.90% of the companies in the same industry.
ALGEN has a Gross Margin of 92.34%. This is amongst the best in the industry. ALGEN outperforms 86.75% of its industry peers.
In the last couple of years the Gross Margin of ALGEN has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.09% | ||
| PM (TTM) | 5.86% | ||
| GM | 92.34% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.73%
GM growth 5Y0.4%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), ALGEN is destroying value.
The number of shares outstanding for ALGEN has been reduced compared to 1 year ago.
ALGEN has more shares outstanding than it did 5 years ago.
ALGEN has a better debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 2.28 indicates that ALGEN is not a great score, but indicates only limited risk for bankruptcy at the moment.
The Altman-Z score of ALGEN (2.28) is better than 68.67% of its industry peers.
The Debt to FCF ratio of ALGEN is 1.41, which is an excellent value as it means it would take ALGEN, only 1.41 years of fcf income to pay off all of its debts.
ALGEN has a better Debt to FCF ratio (1.41) than 86.75% of its industry peers.
A Debt/Equity ratio of 0.26 indicates that ALGEN is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.26, ALGEN is in line with its industry, outperforming 51.81% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.26 | ||
| Debt/FCF | 1.41 | ||
| Altman-Z | 2.28 |
ROIC/WACC0.88
WACC7%
2.3 Liquidity
ALGEN has a Current Ratio of 1.92. This is a normal value and indicates that ALGEN is financially healthy and should not expect problems in meeting its short term obligations.
ALGEN has a Current ratio (1.92) which is comparable to the rest of the industry.
A Quick Ratio of 1.81 indicates that ALGEN should not have too much problems paying its short term obligations.
ALGEN has a Quick ratio of 1.81. This is comparable to the rest of the industry: ALGEN outperforms 45.78% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.92 | ||
| Quick Ratio | 1.81 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 18.41% over the past year.
Looking at the last year, ALGEN shows a quite strong growth in Revenue. The Revenue has grown by 10.04% in the last year.
ALGEN shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 18.46% yearly.
EPS 1Y (TTM)18.41%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%108%
Revenue 1Y (TTM)10.04%
Revenue growth 3Y16.31%
Revenue growth 5Y18.46%
Sales Q2Q%5.92%
3.2 Future
Based on estimates for the next years, ALGEN will show a decrease in Earnings Per Share. The EPS will decrease by 0.00% on average per year.
Based on estimates for the next years, ALGEN will show a quite strong growth in Revenue. The Revenue will grow by 10.37% on average per year.
EPS Next Y-100%
EPS Next 2Y-41.42%
EPS Next 3Y0%
EPS Next 5YN/A
Revenue Next Year-7.14%
Revenue Next 2Y3.51%
Revenue Next 3Y10.37%
Revenue Next 5YN/A
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 12.14, the valuation of ALGEN can be described as correct.
Based on the Price/Earnings ratio, ALGEN is valued cheaper than 90.36% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 26.46, ALGEN is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 12.14 | ||
| Fwd PE | N/A |
4.2 Price Multiples
ALGEN's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. ALGEN is cheaper than 91.57% of the companies in the same industry.
ALGEN's Price/Free Cash Flow ratio is rather cheap when compared to the industry. ALGEN is cheaper than 95.18% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 5.34 | ||
| EV/EBITDA | 4.24 |
4.3 Compensation for Growth
The decent profitability rating of ALGEN may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-41.42%
EPS Next 3Y0%
5. Dividend
5.1 Amount
ALGEN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
EPA:ALGEN (12/5/2025, 7:00:00 PM)
2.55
-0.05 (-1.92%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners5.68%
Inst Owner ChangeN/A
Ins Owners10.39%
Ins Owner ChangeN/A
Market Cap24.17M
Revenue(TTM)22.06M
Net Income(TTM)1.26M
Analysts86.67
Price Target6.02 (136.08%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 12.14 | ||
| Fwd PE | N/A | ||
| P/S | 1.13 | ||
| P/FCF | 5.34 | ||
| P/OCF | 3.5 | ||
| P/B | 1.36 | ||
| P/tB | 1.99 | ||
| EV/EBITDA | 4.24 |
EPS(TTM)0.21
EY8.24%
EPS(NY)0
Fwd EYN/A
FCF(TTM)0.48
FCFY18.74%
OCF(TTM)0.73
OCFY28.58%
SpS2.26
BVpS1.88
TBVpS1.28
PEG (NY)N/A
PEG (5Y)N/A
Graham Number2.98
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.96% | ||
| ROE | 7.06% | ||
| ROCE | 7.62% | ||
| ROIC | 6.13% | ||
| ROICexc | 7.79% | ||
| ROICexgc | 11.35% | ||
| OM | 8.09% | ||
| PM (TTM) | 5.86% | ||
| GM | 92.34% | ||
| FCFM | 21.15% |
ROA(3y)4.35%
ROA(5y)1.91%
ROE(3y)7.98%
ROE(5y)2.79%
ROIC(3y)5.56%
ROIC(5y)N/A
ROICexc(3y)6.94%
ROICexc(5y)N/A
ROICexgc(3y)9.99%
ROICexgc(5y)N/A
ROCE(3y)6.91%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.73%
GM growth 5Y0.4%
F-Score5
Asset Turnover0.68
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.26 | ||
| Debt/FCF | 1.41 | ||
| Debt/EBITDA | 0.77 | ||
| Cap/Depr | 55.06% | ||
| Cap/Sales | 11.1% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 114.18% | ||
| Profit Quality | 360.76% | ||
| Current Ratio | 1.92 | ||
| Quick Ratio | 1.81 | ||
| Altman-Z | 2.28 |
F-Score5
WACC7%
ROIC/WACC0.88
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)18.41%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%108%
EPS Next Y-100%
EPS Next 2Y-41.42%
EPS Next 3Y0%
EPS Next 5YN/A
Revenue 1Y (TTM)10.04%
Revenue growth 3Y16.31%
Revenue growth 5Y18.46%
Sales Q2Q%5.92%
Revenue Next Year-7.14%
Revenue Next 2Y3.51%
Revenue Next 3Y10.37%
Revenue Next 5YN/A
EBIT growth 1Y0.64%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year200%
EBIT Next 3Y68.69%
EBIT Next 5YN/A
FCF growth 1Y308.02%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y1010.09%
OCF growth 3YN/A
OCF growth 5YN/A
GENOWAY SA / ALGEN.PA FAQ
Can you provide the ChartMill fundamental rating for GENOWAY SA?
ChartMill assigns a fundamental rating of 5 / 10 to ALGEN.PA.
Can you provide the valuation status for GENOWAY SA?
ChartMill assigns a valuation rating of 5 / 10 to GENOWAY SA (ALGEN.PA). This can be considered as Fairly Valued.
How profitable is GENOWAY SA (ALGEN.PA) stock?
GENOWAY SA (ALGEN.PA) has a profitability rating of 6 / 10.
How financially healthy is GENOWAY SA?
The financial health rating of GENOWAY SA (ALGEN.PA) is 6 / 10.